Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aliskiren placebo Clear all
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

NCT00518765
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Aliskiren plus placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 14, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

NCT00549757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
8,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
118
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 14, 2026, 8:23 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

NCT01252238
View directory record Official record
Conditions
Insulin Sensitivity, Aortic Compliance, Diastolic Function
Interventions
Aliskiren, Valsartan and Aliskiren, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

NCT00219128
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853
View directory record Official record
Conditions
High Blood Pressure
Interventions
Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction

NCT00982033
View directory record Official record
Conditions
Heart Failure
Interventions
aliskiren, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 14, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

NCT01349114
View directory record Official record
Conditions
Diabetes, Pre-hypertension, Hypertension
Interventions
aliskiren 300 mg once daily, Placebo/sugar pill
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT00894387
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 14, 2026, 8:23 AM EDT
Not listed Phase 4 Interventional

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension

NCT01472796
View directory record Official record
Conditions
Hypertension
Interventions
Vitamin D (cholecalciferol), Tekturna(Aliskiren) plus placebo
Dietary Supplement · Drug
Lead sponsor
Wayne State University
Other
Eligibility
30 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

NCT00414609
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Aliskiren, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Novartis US, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 14, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

NCT00853827
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 14, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

NCT01368536
View directory record Official record
Conditions
Hypertension, Stage 2 Hypertension, Diabetes
Interventions
Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
95
States / cities
Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

The Effect of Renin Inhibition on Nerve Function in Diabetes

NCT00935064
View directory record Official record
Conditions
Diabetes
Interventions
Aliskiren, Placebo
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

NCT01165983
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 14, 2026, 8:23 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Aliskiren Effect on Aortic Plaque Progression

NCT01417104
View directory record Official record
Conditions
Atherosclerosis
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
45 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

NCT00409578
View directory record Official record
Conditions
Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions
Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Investigative Site, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 14, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

NCT00219024
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 14, 2026, 8:23 AM EDT